Ashleigh Barreto
Contacto de Relaciones con Inversores en VIRACTA THERAPEUTICS, INC. .
Cargos activos de Ashleigh Barreto
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | 01/10/2021 | - |
| Public Communications Contact | 01/10/2021 | - |
Historial de carrera de Ashleigh Barreto
Antiguos cargos conocidos de Ashleigh Barreto.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Contacto de Relaciones con Inversores | - | 01/12/2018 |
| Public Communications Contact | - | 01/12/2018 | |
| XOMA CORPORATION | Contacto de Relaciones con Inversores | - | - |
Estadísticas
Internacional
| Estados Unidos | 4 |
Operativa
| Investor Relations Contact | 3 |
| Public Communications Contact | 2 |
Sectorial
| Health Technology | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| XOMA CORPORATION | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Ashleigh Barreto
- Experiencia
